Uterine Artery Embolization for Pedunculated Subserosal Leiomyomas

Evidence of Safety and Efficacy

Yong Seek Kim, Kichang Han, ManDeuk Kim, Gyoung Min Kim, Joon Ho Kwon, Junhyung Lee, Woosun Choi, Jong Yun Won, Do Yun Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To evaluate safety and efficacy of uterine artery embolization (UAE) for pedunculated subserosal (PS) leiomyomas. Materials and Methods: Of 1,069 patients who underwent UAE for symptomatic leiomyomas or adenomyosis from 2007 to 2016, 55 patients (mean age 40.3 y ± 4.8) with 66 PS leiomyomas (mean diameter 6.61 cm ± 2.04) were enrolled. Each PS leiomyoma was categorized into 1 of 2 groups: high-risk PS leiomyoma (stalk diameter < 25% of diameter of leiomyoma) and low-risk PS leiomyoma (stalk diameter 25%–50% of diameter of leiomyoma). MR imaging was performed 3 months after UAE. Rates of infarction and volume reduction were compared between PS leiomyomas and non-PS dominant leiomyomas and between high-risk and low-risk PS leiomyomas. Complications related to PS leiomyomas were assessed. Results: At a median follow-up of 96 days (range, 36–348 d) after UAE, none of the patients (0%) had complications related to PS leiomyomas, even among high-risk cases. Mean volume reductions of 38.2% and 38.4% were achieved for PS leiomyomas and non-PS dominant leiomyomas, respectively (P =.953). There were 3 (5.5%) minor adverse events, but none were related to PS leiomyoma. There was no significant difference in volume reduction and infarction rates between low-risk and high-risk PS leiomyomas. Conclusions: UAE is safe and effective in patients with PS leiomyomas even for high-risk cases (stalk diameter < 25% of diameter of leiomyoma). PS leiomyoma should not be considered a contraindication for UAE.

Original languageEnglish
Pages (from-to)497-501
Number of pages5
JournalJournal of Vascular and Interventional Radiology
Volume29
Issue number4
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Uterine Artery Embolization
Leiomyoma
Safety
Infarction

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Yong Seek ; Han, Kichang ; Kim, ManDeuk ; Kim, Gyoung Min ; Kwon, Joon Ho ; Lee, Junhyung ; Choi, Woosun ; Won, Jong Yun ; Lee, Do Yun. / Uterine Artery Embolization for Pedunculated Subserosal Leiomyomas : Evidence of Safety and Efficacy. In: Journal of Vascular and Interventional Radiology. 2018 ; Vol. 29, No. 4. pp. 497-501.
@article{6da0ddcad5af4f4a9e2e28d0dbdece96,
title = "Uterine Artery Embolization for Pedunculated Subserosal Leiomyomas: Evidence of Safety and Efficacy",
abstract = "Purpose: To evaluate safety and efficacy of uterine artery embolization (UAE) for pedunculated subserosal (PS) leiomyomas. Materials and Methods: Of 1,069 patients who underwent UAE for symptomatic leiomyomas or adenomyosis from 2007 to 2016, 55 patients (mean age 40.3 y ± 4.8) with 66 PS leiomyomas (mean diameter 6.61 cm ± 2.04) were enrolled. Each PS leiomyoma was categorized into 1 of 2 groups: high-risk PS leiomyoma (stalk diameter < 25{\%} of diameter of leiomyoma) and low-risk PS leiomyoma (stalk diameter 25{\%}–50{\%} of diameter of leiomyoma). MR imaging was performed 3 months after UAE. Rates of infarction and volume reduction were compared between PS leiomyomas and non-PS dominant leiomyomas and between high-risk and low-risk PS leiomyomas. Complications related to PS leiomyomas were assessed. Results: At a median follow-up of 96 days (range, 36–348 d) after UAE, none of the patients (0{\%}) had complications related to PS leiomyomas, even among high-risk cases. Mean volume reductions of 38.2{\%} and 38.4{\%} were achieved for PS leiomyomas and non-PS dominant leiomyomas, respectively (P =.953). There were 3 (5.5{\%}) minor adverse events, but none were related to PS leiomyoma. There was no significant difference in volume reduction and infarction rates between low-risk and high-risk PS leiomyomas. Conclusions: UAE is safe and effective in patients with PS leiomyomas even for high-risk cases (stalk diameter < 25{\%} of diameter of leiomyoma). PS leiomyoma should not be considered a contraindication for UAE.",
author = "Kim, {Yong Seek} and Kichang Han and ManDeuk Kim and Kim, {Gyoung Min} and Kwon, {Joon Ho} and Junhyung Lee and Woosun Choi and Won, {Jong Yun} and Lee, {Do Yun}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.jvir.2017.11.022",
language = "English",
volume = "29",
pages = "497--501",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "4",

}

Uterine Artery Embolization for Pedunculated Subserosal Leiomyomas : Evidence of Safety and Efficacy. / Kim, Yong Seek; Han, Kichang; Kim, ManDeuk; Kim, Gyoung Min; Kwon, Joon Ho; Lee, Junhyung; Choi, Woosun; Won, Jong Yun; Lee, Do Yun.

In: Journal of Vascular and Interventional Radiology, Vol. 29, No. 4, 01.04.2018, p. 497-501.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Uterine Artery Embolization for Pedunculated Subserosal Leiomyomas

T2 - Evidence of Safety and Efficacy

AU - Kim, Yong Seek

AU - Han, Kichang

AU - Kim, ManDeuk

AU - Kim, Gyoung Min

AU - Kwon, Joon Ho

AU - Lee, Junhyung

AU - Choi, Woosun

AU - Won, Jong Yun

AU - Lee, Do Yun

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Purpose: To evaluate safety and efficacy of uterine artery embolization (UAE) for pedunculated subserosal (PS) leiomyomas. Materials and Methods: Of 1,069 patients who underwent UAE for symptomatic leiomyomas or adenomyosis from 2007 to 2016, 55 patients (mean age 40.3 y ± 4.8) with 66 PS leiomyomas (mean diameter 6.61 cm ± 2.04) were enrolled. Each PS leiomyoma was categorized into 1 of 2 groups: high-risk PS leiomyoma (stalk diameter < 25% of diameter of leiomyoma) and low-risk PS leiomyoma (stalk diameter 25%–50% of diameter of leiomyoma). MR imaging was performed 3 months after UAE. Rates of infarction and volume reduction were compared between PS leiomyomas and non-PS dominant leiomyomas and between high-risk and low-risk PS leiomyomas. Complications related to PS leiomyomas were assessed. Results: At a median follow-up of 96 days (range, 36–348 d) after UAE, none of the patients (0%) had complications related to PS leiomyomas, even among high-risk cases. Mean volume reductions of 38.2% and 38.4% were achieved for PS leiomyomas and non-PS dominant leiomyomas, respectively (P =.953). There were 3 (5.5%) minor adverse events, but none were related to PS leiomyoma. There was no significant difference in volume reduction and infarction rates between low-risk and high-risk PS leiomyomas. Conclusions: UAE is safe and effective in patients with PS leiomyomas even for high-risk cases (stalk diameter < 25% of diameter of leiomyoma). PS leiomyoma should not be considered a contraindication for UAE.

AB - Purpose: To evaluate safety and efficacy of uterine artery embolization (UAE) for pedunculated subserosal (PS) leiomyomas. Materials and Methods: Of 1,069 patients who underwent UAE for symptomatic leiomyomas or adenomyosis from 2007 to 2016, 55 patients (mean age 40.3 y ± 4.8) with 66 PS leiomyomas (mean diameter 6.61 cm ± 2.04) were enrolled. Each PS leiomyoma was categorized into 1 of 2 groups: high-risk PS leiomyoma (stalk diameter < 25% of diameter of leiomyoma) and low-risk PS leiomyoma (stalk diameter 25%–50% of diameter of leiomyoma). MR imaging was performed 3 months after UAE. Rates of infarction and volume reduction were compared between PS leiomyomas and non-PS dominant leiomyomas and between high-risk and low-risk PS leiomyomas. Complications related to PS leiomyomas were assessed. Results: At a median follow-up of 96 days (range, 36–348 d) after UAE, none of the patients (0%) had complications related to PS leiomyomas, even among high-risk cases. Mean volume reductions of 38.2% and 38.4% were achieved for PS leiomyomas and non-PS dominant leiomyomas, respectively (P =.953). There were 3 (5.5%) minor adverse events, but none were related to PS leiomyoma. There was no significant difference in volume reduction and infarction rates between low-risk and high-risk PS leiomyomas. Conclusions: UAE is safe and effective in patients with PS leiomyomas even for high-risk cases (stalk diameter < 25% of diameter of leiomyoma). PS leiomyoma should not be considered a contraindication for UAE.

UR - http://www.scopus.com/inward/record.url?scp=85042255452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042255452&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2017.11.022

DO - 10.1016/j.jvir.2017.11.022

M3 - Article

VL - 29

SP - 497

EP - 501

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 4

ER -